ORIC Pharmaceuticals Q2 2023 Earnings Report
Key Takeaways
ORIC Pharmaceuticals reported its second quarter 2023 financial results, highlighting steady enrollment in its three clinical trials and the completion of an $85 million private placement financing, ending the quarter with $273.7 million in cash and investments.
Strengthened cash position with $85 million private placement financing.
Initial Phase 1b clinical data for ORIC-114 in EGFR/HER2-mutated cancers to be presented at the ESMO Congress in October 2023.
Initial Phase 1b clinical data expected for ORIC-533 in multiple myeloma in fourth quarter of 2023 and ORIC-944 in prostate cancer in first quarter of 2024.
Ended the quarter with cash and investments of $273.7 million, expected to fund operating plan into late 2025.
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Forward Guidance
The company expects that the cash, cash equivalents and investments of $273.7 million as of June 30, 2023 will be sufficient to fund its current operating plan into late 2025.